Chinese Materia Medica

Chinese materia medica encompasses the medicinal substances used in traditional Chinese medicine and the knowledge concerned with their identification, preparation, and use. Known in Chinese as zhongyao (中药), these substances include plant materials as well as animal-derived and mineral materials. “Chinese herbal medicine” is therefore a common but narrower designation. The subject includes individual medicinal materials and their incorporation into compound preparations, rather than the entirety of Chinese medical practice. (dh.gov.hk)

Its historical literature, commonly called bencao, documents changing classifications, sources, and preparation practices. Works associated with Shennong, Zhang Zhongjing, and Li Shizhen helped shape this tradition, which also influenced medical practice beyond China. Chinese materia medica subsequently became a subject of modern pharmaceutical production, laboratory investigation, and quality standardization. Research on Artemisia annua and the discovery of artemisinin illustrate its significance as a source of leads for drug development. (nlm.nih.gov)

Traditional descriptions of medicinal properties must be distinguished from experimentally established mechanisms and evidence of clinical benefit. Effectiveness and safety depend on the particular substance or formulation, its composition and preparation, and the condition being studied; findings cannot automatically be generalized across the field. The subject consequently spans historical scholarship, medicinal-resource identification, processing and formulation, pharmacology, clinical research, safety surveillance, regulation, and conservation. (nccih.nih.gov)

Terminology and Boundaries

Zhongyao (中药; literally “Chinese medicines”) denotes medicinal substances and preparations used within traditional Chinese medicine, rather than every medicine produced in China. Chinese materia medica emphasizes the medicinal materials themselves and, by extension, the knowledge used to identify, process, classify, and describe them. These usages should be distinguished from the disciplines of pharmacy and pharmacology: a medicinal root is a material object, whereas its preparation and investigation are activities. Modern terminology also distinguishes medicinal materials, decoction pieces, and finished preparations rather than treating them as interchangeable forms of one product. (pmc.ncbi.nlm.nih.gov)

Bencao (本草), conventionally translated as “materia medica,” denotes a historical field of medicinal knowledge and the literature recording it. A bencao text describes such matters as medicinal sources, identification, preparation, and applications; it is not itself a medicinal substance. Although the characters evoke roots and grasses, the literature is not restricted to botanical materials. J. J. Wang’s 1993 discussion characterized bencao as a broad tradition of Chinese pharmaceutical knowledge encompassing what is now called Chinese materia medica. Thus “materia medica” can designate a body of substances, a body of knowledge, or a book genre, depending on context. (pubmed.ncbi.nlm.nih.gov)

“Chinese herbal medicine” is a common English designation, but “herbal” does not fully describe the material range. Alongside plant-derived materials are animal-derived substances and minerals. Hong Kong’s official terminology illustrates the discrepancy: the regulatory category “Chinese herbal medicines” includes mineral substances such as cinnabar (Cinnabaris) and insect materials such as Mylabris. These examples establish the category’s breadth, not therapeutic effectiveness or unrestricted availability. Chinese materia medica is also narrower than traditional Chinese medicine as a whole, which includes diagnostic approaches and non-medicinal practices such as acupuncture and tai chi. (cmro.gov.hk)

Three material levels are particularly important. Medicinal materials, commonly called zhongyaocai (中药材), are source materials following collection and preliminary handling; “raw” in this context does not necessarily mean freshly collected or wholly untreated. Decoction pieces, zhongyao yinpian (中药饮片), are materials prepared for dispensing or further pharmaceutical manufacture through appropriate processing. The term names a pharmaceutical category rather than simply a sliced shape. Finished preparations are products in a completed dosage form, such as pills, tablets, or capsules. A processed ingredient used to manufacture a pill and the resulting pill therefore occupy different levels of description. (pmc.ncbi.nlm.nih.gov)

Technical and legal boundaries are not identical. In Hong Kong, “proprietary Chinese medicine” has a jurisdiction-specific definition involving qualifying active ingredients, a finished dosage form, and specified medicinal claims. Such a definition should not be substituted for the broader scholarly meaning of Chinese materia medica. Likewise, manufacture in China alone does not turn an ordinary synthetic pharmaceutical into zhongyao: geographic production is distinct from classification within a medicinal tradition or regulatory system. (cmro.gov.hk)

Historical Literature and Transmission

The Shennong Bencao Jing (“Divine Husbandman’s Classic of Materia Medica”) is traditionally attributed to Shennong, the legendary agricultural culture hero; that attribution is distinct from the work’s historical compilation, generally placed in the Han dynasty, especially the Eastern Han period (25–220 CE). Its received form contains 365 medicinal entries divided into upper, middle, and lower grades. No original Han manuscript survives intact: the text has been reconstructed from quotations and identifiable textual layers in later compilations. Tao Hongjing (456–536) was particularly important to this transmission. His Bencao Jing Jizhu (“Collected Commentaries on the Classic of Materia Medica”) combined the inherited 365 entries with another 365, producing a collection of 730 substances. He distinguished the older text in red ink from supplementary material in black, allowing subsequent editors to identify different textual layers, although the inherited passages themselves may also have undergone revision. (pmc.ncbi.nlm.nih.gov)

Where materia medica compilations organized information primarily around individual substances, the Shang Han Lun (“Treatise on Cold Damage”), associated with the late-Han physician Zhang Zhongjing, organized compound prescriptions around descriptions of illness. Its contribution was to connect combinations of ingredients with specified constellations of symptoms and signs, while recording their composition, preparation, and circumstances of use within the traditional medical framework. This made prescriptions reproducible as textual units rather than merely lists of medicinal substances. The surviving work is nevertheless a transmitted and edited text, not an unchanged authorial manuscript: the National Library of Medicine holds a revised Song-dynasty version, and the imperial medical-text editorial bureau published an official recension in 1065. The systematic recording and adjustment of compound prescriptions became a central feature of its subsequent reception. (english.scio.gov.cn)

Li Shizhen (1518–1593) compiled the Bencao Gangmu (“Compendium of Materia Medica”) during the Ming dynasty, completing its first draft in 1578 after approximately 27 years of work. Its 52 textual juan, or fascicles, describe 1,892 medicinal substances and record 11,096 prescriptions; two supplementary illustration fascicles contain 1,109 pictures. Li assembled earlier materia medica knowledge, identified quoted authorities, and added observations and corrections. Entries use recurring headings for names and explanations, processing, traditional properties, attributed therapeutic uses, observations, and prescriptions. The work therefore preserves both medicinal descriptions and evidence of how earlier writings were selected and reorganized, including passages from sources subsequently lost. These historical categories and claims should not be equated with modern biological classification or demonstrated clinical efficacy. (media.unesco.org)

Surviving editions are essential evidence for studying that compilation and its circulation. The Jinling edition, block-printed by Hu Chenglong in Nanjing in 1593, was edited by Li’s family and provides an early witness against which later printings can be compared. Its importance lies not only in its contents but also in its arrangement, illustrations, and textual presentation. The Library of the China Academy of Chinese Medical Sciences preserves a copy, while major libraries outside China hold subsequent Ming- and Qing-period editions. Such witnesses allow historians to distinguish the sixteenth-century compilation from changes introduced through later woodblock printing and editorial transmission. (media.unesco.org)

Chinese medical knowledge circulated to the Korean peninsula and Japan through traveling clergy, medical personnel, books, and medicinal materials. Buddhist priests carried Chinese medicine to Korea and Japan before the sixth century, and clerical travel expanded its dissemination during the Tang dynasty (618–907). Korean polities also acted as intermediaries: Baekje adopted Chinese medical offices and dispatched medical personnel to Japan. A prominent Tang-period traveler was Jianzhen (688–763), known in Japan as Ganjin, who reached Japan in 753 on his sixth attempted crossing. Historical accounts associate him with bringing medicinal materials, but the extent of his direct influence on Japanese medical practice remains debated. Transmission thus involved multiple routes and local adaptation, rather than a single introduction by one individual. (nlm.nih.gov)

Medicinal Sources and Material Diversity

Chinese materia medica includes materials of plant, animal, fungal, and mineral origin. Its units are specified medicinal materials, not simply the organisms or geological substances from which they originate. A biological source description therefore identifies both the source species and the part or product collected. One organism can supply several distinct materials: Cinnamomum cassia, for example, provides dried twigs, designated Cinnamomi Ramulus (guizhi), and dried bark, designated Cinnamomi Cortex (rougui). Sharing a botanical source does not make these materials identical. The Hong Kong Chinese Materia Medica Standards likewise distinguish source descriptions from descriptions of the material itself and include separate sections for materials of herbal and mineral origin. (pmc.ncbi.nlm.nih.gov)

Underground botanical materials include roots and rhizomes, which should not be treated as interchangeable anatomical categories. The monograph for Radix Angelicae Sinensis (danggui) defines it as the dried root of Angelica sinensis. Its description distinguishes the root stock, main root, and branching roots, and records features such as longitudinal wrinkles, secretory cavities, and an aromatic odour. Curcumae Longae Rhizoma (jianghuang), by contrast, is obtained from the rhizome of Curcuma longa: the medicinal organ is an underground stem rather than a root. Health Canada’s ingredient record explicitly specifies “rhizome” as its source material, while Kew’s Medicinal Plant Names Services connects this material with the 2014 Hong Kong standards and the 2010 and 2015 Chinese pharmacopoeias. (dh.gov.hk)

Above-ground materials are similarly differentiated by organ and developmental stage. Bark is represented by Cinnamomi Cortex; leaves by Ginkgo Folium, the dried leaves of Ginkgo biloba. The latter retain a characteristic fan-shaped outline and branching veins, although commercial specimens may be wrinkled or fragmented. Lonicerae Japonicae Flos (jinyinhua) comprises dried flower buds or newly opening flowers of Lonicera japonica, rather than unrestricted collections of the plant’s flowers. Fruits and seeds form separate categories: Schisandrae Chinensis Fructus (wuweizi) is the dried ripe fruit of Schisandra chinensis, whereas Cassiae Semen (juemingzi) consists of ripe seeds from Cassia obtusifolia or C. tora, named Senna obtusifolia and S. tora in Kew’s accepted taxonomy. These examples show why a material specification must state more than a common plant name. (sys01.lib.hkbu.edu.hk)

Fungal materials do not fit a strictly botanical classification by roots, leaves, and flowers. Poria, traditionally associated with the name Poria cocos, is derived from a sclerotium. Different portions have distinct material names: the outer covering is Poria Cutis (fulingpi), the inner portion is baifuling, and material retaining attached host wood is fushen. This division demonstrates that material diversity can arise within a single fungal structure, not only through the use of different species. (scholars.hkbu.edu.hk)

Animal-derived materials include structures shed by an animal as well as shells. The Taiwan Herbal Pharmacopoeia defines Cicadae Periostracum (chantui) as dried cicada nymphal exuviae collected after emergence, identifying Cryptotympana pustulata as its source. Its description records a hollow, translucent, yellowish-brown body approximately 2–4 cm long, with a split dorsal surface and recognizable leg structures. Ostreae Concha (muli) is oyster shell, not oyster flesh; the Hong Kong Polytechnic University’s material entry lists three oyster sources under the names Ostrea gigas, O. talienwhanensis, and O. rivularis. Such entries document material identity and inclusion in medicinal collections, rather than establishing clinical efficacy or permission to trade a specimen in any particular jurisdiction. (mohw.gov.tw)

Mineral materials require compositional and physical descriptions instead of botanical identification. Gypsum (shigao) is a sulfate mineral consisting principally of calcium sulfate dihydrate, $\mathrm{CaSO_4\cdot 2H_2O}$. Its description therefore concerns mineral composition and features such as colour, crystal form, cleavage, and texture, rather than plant organs or a source organism. The Hong Kong standards’ mineral section separately lists materials including Cinnabaris, Realgar, Orpiment, and Arsenolite: “mineral origin” is a broad source category, not a single chemical identity. A mineral name, chemical composition, and description of the actual medicinal specimen serve complementary purposes. (herbaltcm.sn.polyu.edu.hk)

Names, Identity, and Authentication

A Chinese medicinal name identifies a recognized material, not necessarily a single biological species. Its written Chinese characters, pinyin romanization, pharmaceutical Latin name, and scientific species name serve different purposes. For example, 甘草, gancao, corresponds to the pharmaceutical name Glycyrrhizae Radix et Rhizoma, which denotes root and rhizome material; Glycyrrhiza uralensis identifies one botanical source. The Chinese Pharmacopoeia editions of 2005 and 2010 also recognized G. glabra and G. inflata as sources of gancao. Thus, a pharmaceutical name can cover several specified species while remaining more restrictive than an informal trade name. Hong Kong’s monograph framework separates “names” from “source,” with the latter specifying botanical origin, family, medicinal part, and condition. (cmro.gov.hk)

Names require interpretation across regions and historical periods. Different communities may use different names for the same plant, while one vernacular name may denote several plants; romanization alone does not resolve these ambiguities. Scientific names also accumulate synonyms through changes in taxonomy, so an older botanical name need not indicate a different organism. Kew’s Medicinal Plant Names Services links names as printed in medicinal references to accepted scientific names and their synonyms, retaining information about the source publication, medicinal part, and material form. A documented example of consequential confusion occurred at a Belgian slimming clinic in the early 1990s, where Aristolochia fangchi, called guang fang ji, replaced the intended Stephania tetrandra, called han fang ji. The similar names concealed distinct botanical identities. (kew.org)

Physical authentication begins with comparison against a pharmacopoeial description and authenticated reference material. Macroscopic examination records shape, dimensions, surface markings, colour, texture, fracture, and the appearance of cut surfaces. Examination with a microscope investigates tissue structures in sections or diagnostic fragments in powders, particularly where cutting or grinding has removed recognizable external features. The World Health Organization specifies that authentic specimens and pharmacopoeial-quality samples should be available for comparison, while emphasizing that microscopy alone cannot always establish complete identity. Hong Kong’s standards combine macroscopic descriptions with microscopic, physicochemical, and chromatographic identification tests rather than treating visual resemblance as sufficient. (who.int)

DNA barcoding adds evidence about biological origin by comparing a selected DNA sequence with reference sequences from identified specimens. In 2010, Shilin Chen and colleagues tested the nuclear ribosomal ITS2 region in more than 6,600 samples representing 4,800 species and reported 92.7% successful species-level identification in that dataset—not a universal accuracy rate for all medicinal materials. Reference-library construction is therefore integral to the method. A 2018 study of southern Chinese medicinal plants assembled 1,276 ITS2 sequences representing 309 species, with voucher specimens deposited at the Guangdong Provincial Hospital of Traditional Chinese Medicine. Such vouchers provide a physical basis for checking the taxonomic identification attached to a sequence. (pubmed.ncbi.nlm.nih.gov)

Molecular and conventional methods answer overlapping but different questions. DNA identification does not by itself establish the medicinal part or processing condition specified in a monograph. Processing can also leave insufficient intact DNA: a 2021 investigation of commercial decoction pieces obtained barcodes from 161 of 212 samples, or 75.9%, with failures attributed to genomic DNA degradation. Conversely, reference libraries require scrutiny because incorrectly identified sequences can misdirect comparisons. A 2022 Hong Kong laboratory study addressed reference reliability through documented specimen provenance, up to three barcode regions per specimen, independent measurements, and inter-laboratory validation. (dh.gov.hk)

An authorized alternative source is a species expressly included in the applicable material specification; it is not an adulterant merely because another permitted species is more familiar. Accidental substitution results from mistaken identification or handling, whereas deliberate adulteration involves intentional misrepresentation; an identity test establishes a mismatch but does not alone establish intent. For experimental reproducibility, the medicinal name must therefore be connected to the actual source species, part, material condition, and authenticated sample. Otherwise, studies nominally examining the same ingredient may investigate different biological materials. WHO manufacturing guidance accordingly calls for identification methods capable of distinguishing the required material from likely substitutes and adulterants, supported by comparative reference samples. (dh.gov.hk)

Cultivation, Collection, and Geographic Provenance

*Daodi* medicinal materials are associated with particular production regions and established practices of cultivation, harvesting, and initial processing. The designation is historically developed: it combines geographic reputation, local environmental conditions, accumulated production knowledge, and recognition within medicinal trade, rather than identifying botanical origin alone. Zhongzhen Zhao, Ping Guo, and Eric Brand’s 2012 review, The formation of daodi medicinal materials, examined this relationship through historical literature, market investigation, and fieldwork. Although superior quality and clinical effects form part of the traditional reputation of daodi materials, the designation itself is not comparative clinical evidence. Its environmental and production components can instead be treated as separately testable characteristics. (scholars.hkbu.edu.hk)

Cultivation and wild collection represent distinct routes of supply. Cultivation permits deliberate selection of planting stock and management of soil, irrigation, fertilizer, and crop protection; wild collection involves locating and gathering plants from existing populations. The World Health Organization’s 2003 good agricultural and collection practices guidelines distinguish both routes from subsequent handling. Records of cultivation conditions or collection sites establish the circumstances in which material was produced, while harvest dates identify its developmental stage. These details matter because the same species can yield chemically different material under different growing and harvesting conditions. (iris.who.int)

Harvest timing can affect both biomass and constituent concentrations, and these outcomes need not reach their maximum together. A 2024 study of danshen (Salvia miltiorrhiza) grown in Mississippi compared harvests at 60, 120, and 180 days after transplanting during 2020 and 2021. Plants harvested at 180 days generally had greater root growth and weight; roots harvested at 120 or 180 days contained higher concentrations of tanshinone I, tanshinone IIA, cryptotanshinone, and salvianolic acid B than those harvested at 60 days. A separate experiment by Chun-e He and colleagues, published in 2010, grew three danshen germplasm lines originating in Shaanxi, Shandong, and Henan at one location in Beijing. Measurements during 2008–2009 showed that constituent accumulation varied with germplasm, year, and harvest time, producing different optimum harvest dates for the three lines. These are agronomic findings, not demonstrations of therapeutic superiority. (pmc.ncbi.nlm.nih.gov)

Investigating geographic provenance therefore requires distinguishing where a batch actually grew from the geographic ancestry of its planting stock. The Beijing danshen experiment illustrates a common-site design that reduces environmental differences when comparing germplasm. Conversely, comparisons between production regions must account for plant age, harvest season, and cultivation practices before attributing chemical differences to location. Chromatographic measurements can establish constituent profiles and concentrations, but interpretation depends on this accompanying production information. A regional name on a commercial label cannot substitute for documented origin, and a higher concentration of selected constituents does not independently establish greater clinical effectiveness. (doi.org)

Initial post-harvest handling includes removing soil and foreign matter, sorting, and prompt transfer to processing facilities. Drying reduces moisture-related deterioration, but its temperature and duration can also alter material characteristics; WHO guidance specifically notes the vulnerability of volatile constituents and calls for drying conditions to be recorded. Traceability links these operations to the source through records of botanical identity, production or collection location, harvest date, agricultural inputs, handling, and batch identification. Such documentation connects a delivered lot to its field or collection area rather than merely to its last seller, and preserves the information needed to investigate differences between batches. (iris.who.int)

Traditional Properties and Functional Classification

The four natures, siqi (四氣), classify medicinal materials as cold, cool, warm, or hot within traditional Chinese medicine. “Neutral,” ping (平), is an additional designation for materials without a pronounced cold or hot character. These terms describe attributed effects in relation to traditional cold and heat patterns, not the measured temperature of a substance or its preparation. Within this framework, cold and cool materials counter heat patterns, whereas warm and hot materials counter cold patterns. Hong Kong Baptist University’s material database, for example, describes rhubarb (dahuang) as bitter and cold, and liquorice root (gancao) as sweet and neutral. Neither designation specifies whether a preparation is served hot or cold. (healthbureau.gov.hk)

The five flavors, wuwei (五味), are sour, bitter, sweet, pungent, and salty. They combine descriptions of taste with conventional assignments of function, rather than constituting a sensory measurement alone. In traditional terminology, sour materials restrain or astringe; bitter materials drain, purge, or dry “dampness”; sweet materials supplement, harmonize, or moderate tension; pungent materials disperse and promote the movement of qi and blood; and salty materials soften hardness and promote downward discharge. These are explanations internal to the traditional system, not established biochemical mechanisms. A material may carry more than one flavor designation: the HKBU database describes ginseng root as sweet and slightly bitter, with a slightly warm nature, but describes its leaves as bitter, sweet, and cold. Classification thus attaches to the particular medicinal material, not automatically to every part of its source plant. (build.fhir.org)

Channel affiliation, guijing (歸經), also translated as meridian affinity or tropism, identifies the traditional organ systems and channels to which a material’s action is assigned. It is grounded in the zang–fu and channel theories of Chinese medicine, rather than in a demonstrated distribution of chemical constituents to anatomical organs. “Lung,” “Spleen,” or “Kidney” in such descriptions therefore denotes a traditional functional system. The separate tendencies of ascending, descending, floating, and sinking—sheng, jiang, fu, chen (升降浮沉)—describe attributed upward, downward, outward, and inward directions of action. HKBU’s account of the formula Sang Ju Yin, for example, contrasts apricot seed’s assigned role of descending Lung qi with balloonflower root’s role of diffusing it; this documents traditional reasoning rather than a measured transport process. (healthbureau.gov.hk)

Functional groupings organize materials by their principal traditional uses. Exterior-releasing substances are assigned to exterior patterns, including wind-cold and wind-heat; the distinction is reflected in pungent-warm and pungent-cool groupings. Mulberry leaf, chrysanthemum flower, and mint appear in Sang Ju Yin with assigned wind-heat-dispersing or exterior-releasing roles. Heat-clearing substances are described as removing traditional heat or fire, sometimes with additional qualifications such as drying dampness. Such terms should not be treated as synonyms for antipyretic, anti-inflammatory, or antimicrobial activity in pharmacology. The World Health Organization published standardized Chinese-medicine terminology on March 3, 2022, to support consistent communication and documentation of these concepts. (researchgate.net)

Purgative and tonifying classifications describe different traditional objectives. Rhubarb is assigned bowel-relaxing and accumulation-discharging functions, whereas ginseng root is described as supplementing original qi and supporting the Spleen and Lung systems. Tonifying substances are further differentiated according to qi, blood, yin, or yang deficiency, rather than grouped as an undifferentiated stimulant class. Functional categories also overlap: liquorice is described as supplementing qi, clearing heat, relieving cough, and harmonizing other medicinals. Its record illustrates why a principal classification does not exhaust a material’s traditional functions, and why nature, flavor, channel affiliation, and directional tendency are recorded together rather than used as mutually exclusive categories. (sys01.lib.hkbu.edu.hk)

Processing of Medicinal Materials

Paozhi (炮制) denotes the pharmaceutical processing of individual medicinal materials into forms suitable for dispensing or subsequent preparation. Its scope includes physical operations, such as cleaning and cutting, and treatments intended within traditional Chinese medicine to modify a material’s properties or reduce toxicity. The resulting products are commonly called “decoction pieces” (yinpian), although processing is not restricted to slicing. Processing a particular root with honey, for example, is distinct from combining that root with other ingredients in a compound prescription or manufacturing the finished prescription as pills or granules. Processing status therefore forms part of an ingredient’s identity, rather than merely describing its packaging or dosage form. (cmro.gov.hk)

Operations range from removing foreign matter and unwanted parts to washing, moistening, cutting, drying, stir-frying, steaming, boiling, and calcining. They are selected for particular materials rather than applied as a universal sequence. Cleaning separates usable material from impurities; cutting produces pieces suitable for handling and extraction; drying follows treatments that introduce moisture. More transformative procedures employ heat alone or processing aids, including wine, vinegar, ginger juice, honey, and salt solutions. Documented examples include honey-roasted licorice, vinegar-baked Euphorbia kansui root, and water-treated aconite roots. These names identify materially different products: “honey-roasted” records both an added substance and a heat treatment, whereas “vinegar-baked” distinguishes a treated root from its untreated counterpart. (pmc.ncbi.nlm.nih.gov)

Traditional explanations describe processing as changing functional tendencies, strengthening selected actions, moderating harsh properties, or reducing toxicity. These explanations must be distinguished from measurements of chemical composition and extractability. In a study published online in December 2011 and collected in a 2012 journal issue, Mengyue Wang and colleagues compared crude and honey-roasted licorice using high-performance liquid chromatography. They measured five glycosides—liquiritin apioside, liquiritin, licuraside, isoliquiritin, and glycyrrhizin—in the material and its water decoction. Honey-roasting altered both their concentrations and the quantities recovered during decoction; experiments also demonstrated decomposition of glycyrrhizin and liquiritin under the tested treatment. Animal assays showed changes in several biological activities, but these findings did not establish corresponding clinical effects in humans. The distinction between constituent content and extraction yield is important: the amount present in a processed slice is not necessarily the amount transferred into a preparation. (pubmed.ncbi.nlm.nih.gov)

Aconite provides a specific example of processing-related chemical transformation. In 2013, Yogini Jaiswal, Zhitao Liang, Peng Yong, Hubiao Chen, and Zhongzhen Zhao compared processing methods applied to roots of three Aconitum species. Using liquid chromatography coupled with mass spectrometry, they documented removal of diester diterpenoid alkaloids and conversion into monoester derivatives through hydrolysis. This supplies experimental evidence for a reduction in particular toxic constituents, not proof that every processed aconite product is harmless. Monoester alkaloids remain biologically active and potentially toxic; a separate 2013 investigation explicitly identified benzoylaconine, benzoylmesaconine, and benzoylhypaconine as active and toxic constituents of processed aconite. (pubmed.ncbi.nlm.nih.gov)

Raw and processed forms consequently require specifications that distinguish their treatment history, appearance, and relevant chemical characteristics. A single marker or a generic label such as “processed” may not adequately describe the transformation. In 2023, Hui Ni and colleagues investigated vinegar-baked Euphorbia kansui: they screened 310 differential compounds, but only a small subset met their combined criteria of correlation, significant difference, and controllability for processing markers. Such studies illustrate why process control requires experimentally evaluated indicators rather than assumed chemical changes. Processing also cannot compensate for a subsequent identity failure: on April 28, 2012, Hong Kong’s Department of Health ordered a recall of processed Radix Aconiti Lateralis contaminated with another processed aconite material, Radix Aconiti. Both contained aconitum alkaloids, demonstrating that processing status and correct material identity remain separate quality requirements. (pubmed.ncbi.nlm.nih.gov)

Compound Formulas and Prescription Organization

A single medicinal substance is an ingredient; a compound formula (fangji) specifies how several ingredients are combined for a stated purpose within traditional Chinese medicine. Formula records distinguish the prescription’s name and textual source, ingredient identities and quantities, preparation method, traditional actions, and indicated diagnostic patterns. These fields describe different aspects of the prescription: a list of ingredients alone does not identify its proportions or preparation, while a traditional indication is not evidence of clinical efficacy. Hong Kong Baptist University’s formula database, launched in April 2018, organizes this information alongside diagrams of ingredient relationships, making the distinction between composition and traditional interpretation explicit. (hkbu.edu.hk)

The traditional organizing framework assigns ingredients four roles: monarch (jun), minister (chen), assistant (zuo), and envoy (shi). The monarch addresses the principal pattern; the minister reinforces that purpose or addresses an important accompanying feature. The assistant supports the main ingredients, addresses secondary features, or traditionally restrains undesirable effects. The envoy is described as directing the formula toward a particular channel or region, or harmonizing its ingredients. These are explanatory roles within traditional prescription theory, not demonstrated molecular mechanisms. In Si Jun Zi Tang (Four Gentlemen Decoction), the database identifies ginseng as monarch, largehead atractylodes rhizome as minister, poria as assistant, and honey-processed licorice as envoy. Their respective traditional functions concern supplementing qi, supporting the “spleen,” draining “dampness,” and harmonizing the prescription; these terms refer to traditional functional concepts rather than direct descriptions of anatomical organs or measured physiology. (jf2.hep.com.cn)

Classical formulas also provide starting points for named modifications. Si Jun Zi Tang is recorded in the imperial-pharmacy collection Tai Ping Hui Min He Ji Ju Fang. Its traditional indication is “spleen–stomach qi deficiency,” a pattern described through features such as poor appetite, fatigue, a pale tongue, and a weak pulse. Liu Jun Zi Tang (Six Gentlemen Decoction), recorded in Yi Xue Zheng Zhuan, retains its four core ingredients and adds tangerine peel (chen pi) and pinellia rhizome (ban xia). The modification is traditionally associated with the additional feature of “phlegm–dampness.” The historical preparation of Four Gentlemen involved powdered materials subsequently decocted, whereas the database also records modern use as a decoction. Thus, continuity of a formula name does not necessarily mean continuity of preparation form. (sys01.lib.hkbu.edu.hk)

Fixed-composition proprietary preparations differ from prescriptions modified during individual dispensing: the finished product has a specified ingredient composition and dosage form. A classical prescription may supply its underlying formula, but the product and historical prescription remain distinct objects of documentation. HKBU’s specimen collection, for example, includes Liu Wei Di Huang Wan as a proprietary medicine. Hong Kong’s regulatory definition identifies proprietary Chinese medicines as finished-dose products composed of specified categories of Chinese medicinal ingredients and carrying medicinal or bodily-function claims; it does not require every such product to be multi-ingredient. Registration documentation separately records ingredient quantities and permits their ordering either by quantity or by traditional prescription role. (sys01.lib.hkbu.edu.hk)

Traditional compatibility terminology distinguishes combinations intended to reinforce effects, restrain unwanted effects, or produce antagonism; named prohibitions include the “eighteen incompatibilities” and “nineteen fears.” Such classifications must be separated from experimentally observed interactions. In a 2013 study, Karoline Peter and colleagues investigated a modified Sini Tang preparation and demonstrated complex formation between aconitine and the licorice constituent liquiritin using chromatographic and spectroscopic methods. The complex had a 1:1 stoichiometry under the tested conditions. This was a specific chemical finding, not proof that licorice universally neutralizes aconite toxicity or that every preparation of the formula is safe. Experimental interaction claims therefore require the precise materials, processing states, proportions, extraction conditions, and measured endpoints, rather than merely the traditional compatibility label. (iris.who.int)

Dosage Forms and Pharmaceutical Manufacture

A dosage form describes the physical preparation in which medicinal ingredients are supplied, rather than their botanical, animal, or mineral identity. Decoctions are liquid preparations obtained by extracting medicinal materials in heated water. Powders may consist of finely ground materials or dried extracts: these are distinct preparations, since grinding retains the material itself whereas extraction transfers selected constituents into a liquid before drying. Pills are rounded solid preparations made from medicinal powders or extracts with suitable binding ingredients; tablets are formed by compression, and capsules enclose powders, granules, or, in some designs, liquid or soft extracts. Extracts may be liquid, semisolid, or dry and can serve as intermediate materials for several finished forms. Granules comprise agglomerated particles, commonly incorporating dried extracts and excipients. Thus, a capsule and a tablet may contain the same type of extract, while two visually similar powders may have substantially different manufacturing histories. (who.int)

Individual dispensing and industrial manufacture operate at different levels of preparation. A pharmacy may assemble processed medicinal materials according to a particular prescription, prepare a decocted liquid, or combine manufactured granules for that prescription. Industrial production instead manufactures defined batches under a master formula and specified processing conditions. These arrangements can overlap: prescription-specific dispensing may use ingredients already extracted and granulated by a factory. The Hong Kong Health Bureau’s hospital-pharmacy plan explicitly distinguished processed medicinal materials, granules, proprietary medicines, decocted medicines, and compounded preparations, with dispensing and preparation performed according to practitioners’ prescriptions. The distinction is therefore not simply “traditional preparation” versus “factory product,” but also whether composition is determined for an individual prescription or established for a manufactured batch. (healthbureau.gov.hk)

Extraction, concentration, and drying establish important characteristics of an extract-based product. Specifications identify the starting material, extraction solvent, extraction method, and subsequent processing. Solvent composition, material particle size, temperature, and extraction duration influence which constituents enter the extract and how reproducibly they are recovered. Concentration removes solvent; drying produces a solid intermediate that may subsequently be blended with excipients and made into granules, tablets, or capsules. Manufacturing documentation must distinguish the quantity of medicinal material used from the quantity of extract obtained and from the final product mass, which may include nonmedicinal excipients. The World Health Organization’s 2018 processing guidance treats extraction and dosage-form production as separate, documented stages rather than interchangeable descriptions of the ingredient. (who.int)

Blending aims to distribute materials uniformly within an intermediate or finished product. WHO manufacturing guidance requires documentation of blending operations and controls against using blending merely to conceal substandard material. Packaging is likewise part of manufacture: containers must be suitable for their contents, packaging operations must prevent product and label mix-ups, and batch identification must remain traceable. Storage conditions are established through stability assessment rather than inferred from the material’s traditional name. WHO guidance specifically identifies suitable containers, temperature, humidity, and protection from light as considerations for herbal materials and products; finished-product stability also supports the assigned shelf life and labelled storage conditions. (who.int)

Good manufacturing practice (GMP) provides an organized system for controlling premises, equipment, personnel, sanitation, documentation, manufacture, and quality release. Hong Kong issued its GMP guidelines for proprietary Chinese medicines in 2003. Process validation requires documented evidence that defined procedures consistently achieve their intended results; its guidelines specify validation when a new master formula or manufacturing method is introduced and when significant changes could affect quality. Batch records connect the materials used with processing operations, checks, yields, and packaging. Recall procedures then use distribution records to identify recipients of an affected batch, retrieve defective or suspected defective products, and reconcile quantities distributed and recovered. Hong Kong’s guidelines require recalled products to be securely segregated and the effectiveness of the recall system to be evaluated regularly. (cmro.gov.hk)

Chemical Constituents and Laboratory Characterization

Chemical descriptions distinguish the whole medicinal material from an extract, a fraction, and a purified compound. An extract contains substances transferred from the source material into a specified solvent; a fraction is a subset separated from that extract, whereas a purified compound is an individual chemical substance with an established identity and measured purity. These are not interchangeable research materials: extraction and fractionation change their composition. Constituent classes include alkaloids, such as berberine and palmatine in Coptis rhizomes; flavonoids, such as hesperidin in citrus peel; terpenoids and their glycosides, including saikosaponins in Bupleurum roots; and lignans, such as schisandrin in Schisandra fruits. Class names describe chemical structure, not a shared therapeutic effect. (ema.europa.eu)

Chromatography separates constituents through their different interactions with stationary and mobile phases. Thin-layer chromatography produces patterns of spots compared with reference substances or authenticated materials; high-performance liquid chromatography (HPLC) produces peaks whose retention times and detector responses support identification and quantification. A peak’s position alone does not establish molecular identity. Hong Kong’s first Chinese Materia Medica Standards volume, published in July 2005, incorporated thin-layer chromatography and HPLC fingerprinting for eight medicinal materials representing nine species. These included ginseng, notoginseng, Salvia miltiorrhiza root, and two botanical sources of Phellodendron bark. (dh.gov.hk)

Mass spectrometry provides complementary information through the mass-to-charge ratios of ions and their fragmentation patterns. Coupling liquid chromatography to mass spectrometry helps distinguish constituents within complex extracts. Spectroscopic methods supply additional evidence: ultraviolet absorption spectra help characterize chromatographic peaks, while nuclear magnetic resonance provides information about molecular structure. In a 2010 investigation of the 20-ingredient preparation IBS-20, researchers checked reference compounds using mass spectrometry and nuclear magnetic resonance and established purity above 98%. Constituents in the finished extract were identified through combined retention-time, fragmentation, and ultraviolet-spectral evidence rather than a single analytical signal. (pmc.ncbi.nlm.nih.gov)

An analytical marker is selected for identification, measurement, or monitoring; its use does not necessarily mean that it causes biological activity. The World Health Organization’s 2017 guidelines distinguish markers associated with known therapeutic activity, recognized pharmacological activity, characteristic composition, and toxic constituents. Selection depends on specificity, availability, stability, and reliable detection in the preparation being tested. A compound measurable in a raw material may be unsuitable in a finished extract because extraction removes it or other ingredients interfere with its detection. Demonstrating laboratory activity and establishing a contribution to therapeutic effects are also different evidential claims. WHO accordingly treats marker identification and quantification as insufficient, by themselves, to guarantee overall quality. (who.int)

A chromatographic fingerprint records a pattern of multiple peaks under defined conditions, allowing comparison with reference materials or between batches. It complements individual constituent assays and can reveal compositional changes during storage. Nevertheless, the pattern is method-dependent: extraction solvent, separation conditions, and detector response determine which constituents appear. In IBS-20, mass-spectral analysis identified 20 markers attributable to ten of its 20 ingredients, illustrating that a measured profile need not represent every source material. Similar fingerprints therefore establish similarity within the analytical method’s coverage, not independently demonstrated clinical equivalence. Even compliance with specified marker limits does not, by itself, establish complete batch-to-batch uniformity; European regulatory guidance also requires attention to constituents beyond the chosen markers when evaluating stability. (pmc.ncbi.nlm.nih.gov)

Pharmacology and Mechanistic Investigation

Experimental pharmacology examines defined materials, extracts, formulas, or purified constituents rather than Chinese materia medica as a single intervention. Biochemical assays can measure inhibition of an enzyme or interaction with a purified protein; cultured cells reveal effects on signaling, proliferation, differentiation, or survival. These measurements require controls that distinguish biological activity from interference with the detection system. A compound may react with assay reagents or alter a reporter enzyme without affecting the intended target. Confirmation through an independent assay using a different detection principle therefore strengthens a mechanistic claim. The Assay Guidance Manual, published through the US National Center for Advancing Translational Sciences and collaborating institutions, describes such interference and methods for separating genuine activity from misleading readouts. (ncbi.nlm.nih.gov)

Animal experiments investigate activity within an intact organism, including tissue responses and the relationship between administered material and biological effects. Their interpretation depends on the selected disease model, route of administration, dose, timing, and comparison groups. Technical guidelines published in 2025 by Weijie Li and colleagues specify documentation of formula composition, source materials, medicinal parts, processing, and preparation methods, so that the experimental sample corresponds to the preparation being investigated. They also emphasize reproducible models, measurable outcomes, and controlled experimental design. An effect in a model establishes an observation under those experimental conditions; whether it translates to human treatment requires separate investigation. (pmc.ncbi.nlm.nih.gov)

Pharmacokinetics connects administered quantities with exposure through absorption, distribution, metabolism, and elimination. Human pharmacological studies measure concentration–time profiles and identify circulating metabolites, which may differ from the compounds originally present in a preparation. In a 2022 randomized crossover study, Yavuz Yagiz, Gary P. Wang, and Liwei Gu examined berberine formulations in 12 healthy participants. Following an experimental 800-mg dose of berberine powder, peak plasma concentration was approximately 0.9 nM; emulsification with Quillaja extract increased it to 5.1 nM. Exposure over 12 hours, measured as area under the concentration–time curve, increased from 6.7 to 28.0 nM·h. Berberrubine and demethyleneberberine were major detected metabolites. These results demonstrate that formulation can change systemic exposure, but do not independently establish therapeutic benefit. Laboratory concentrations must therefore be evaluated against measured exposure rather than assumed to occur after oral administration. (pubmed.ncbi.nlm.nih.gov)

Measured mechanisms are distinguished from proposed mechanisms by experiments that test causal involvement, not merely accompanying changes in gene expression or signaling. Lan Wang and colleagues’ 2008 investigation of Realgar–Indigo naturalis formula examined tetraarsenic tetrasulfide, indirubin, and tanshinone IIA individually and in combinations, using leukemia cells and a mouse model of acute promyelocytic leukemia. The combination increased expression of the arsenic transporter AQP9 and intracellular arsenic accumulation in NB4 cells. Silencing AQP9 with small interfering RNA reduced arsenic uptake and the differentiation response, supporting a functional contribution from that transporter. This provides a specific example of experimentally investigated constituent interactions. Nevertheless, results for a reconstructed combination of selected compounds are not automatically results for every constituent or batch of the original formula; whole-preparation effects require investigation of the whole preparation itself. (pmc.ncbi.nlm.nih.gov)

Network pharmacology organizes relationships among constituents, predicted or recorded targets, pathways, and diseases. Jinlong Ru and colleagues’ 2014 description of the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) reported 499 medicinal herbs, 29,384 ingredients, 3,311 targets, and 837 associated diseases, together with properties relevant to absorption and metabolism. Such databases support candidate selection and construction of testable hypotheses. Computational target assignments, modeled absorption, and interaction networks must remain distinguishable from experimentally measured binding, exposure, and target dependence. Predicted relationships can direct biochemical and cellular experiments, but cannot replace them: computational models provide clues rather than experimental proof, and neither a predicted target nor a confirmed molecular interaction independently establishes clinical efficacy. (tcmsp-e.com)

Clinical Evidence and Research Design

Clinical efficacy findings concern a defined intervention in a defined population, rather than Chinese materia medica as a single therapeutic category. Relevant specifications include ingredient identity, processing, formulation, dose, treatment duration, medical indication, comparator, and outcome. The CONSORT Extension for Chinese Herbal Medicine Formulas, published in 2017 by Chung-wah Cheng and colleagues, distinguishes fixed, individualized, and proprietary formulas and specifies reporting requirements for each. It also asks investigators to state whether recruitment targets a biomedical disease, a traditional diagnostic pattern, or both. These distinctions limit the transfer of findings between preparations that share a traditional name but differ in composition or manufacture. An adjunctive trial comparing a formula plus conventional treatment with conventional treatment alone addresses incremental benefit; it does not establish that the formula can replace that treatment. (doi.org)

A randomized controlled trial uses an unpredictable allocation sequence and concealed assignment to reduce selection bias. Blinding participants, clinicians, and outcome assessors addresses additional biases arising after assignment. Interpretation depends on prespecified outcomes, participant withdrawals, adherence, and analysis of the assigned groups—not simply on whether a reported difference is statistically significant. Clinically meaningful outcomes include symptom relief, daily functioning, quality of life, hospitalization, or survival, as appropriate to the indication. The estimated effect size and its confidence interval indicate both magnitude and uncertainty. Small samples can leave confidence intervals compatible with materially different conclusions. Adverse-event reporting likewise requires defined collection methods, events and denominators for each group, and withdrawals caused by harms; a statement that treatment was “well tolerated” provides less information. (pmc.ncbi.nlm.nih.gov)

Formulation variability and individualized prescribing create particular challenges for reproducibility. The 2017 CONSORT extension calls for documentation of medicinal ingredients, processing, quantities, production, and the modifications made to individualized prescriptions. Herbal placebos must approximate appearance, smell, taste, and packaging without reproducing the intervention’s active properties. Alan Bensoussan and colleagues demonstrated one approach to studying individualized treatment in a 1998 Australian trial of 116 adults meeting Rome criteria for irritable bowel syndrome. Participants received a standardized herbal preparation, an individualized preparation, or placebo for 16 weeks. Both herbal groups showed improvement relative to placebo during treatment on the reported symptom assessments, but individualized treatment was not significantly superior to standardized treatment. Only the individualized group maintained improvement at the assessment 14 weeks after treatment ended. These results concern the tested preparations, population, and follow-up periods rather than all formulas used for bowel symptoms. (doi.org)

A systematic review identifies eligible studies through explicit search and selection procedures, assesses their risk of bias, and determines whether their results can meaningfully be combined. Differences in ingredients, administration routes, comparators, and outcome definitions may make a pooled estimate difficult to interpret. A 2013 Cochrane review of Chinese herbal medicine for atopic eczema included 28 studies involving 2,306 participants: four compared herbal treatment with placebo, 22 with conventional medicines, and two with oral herbal treatment. Most studies were judged at high risk of bias, particularly concerning blinding, and results were substantially inconsistent. Although some comparisons favored herbal interventions, the reviewers found no conclusive evidence that oral or topical Chinese herbal medicine reduced eczema severity. The review illustrates why positive findings from small studies do not necessarily yield reliable evidence when considered together. (doi.org)

The United States National Center for Complementary and Integrative Health describes findings from studies of Chinese herbal products across medical conditions as mixed and states that poor study quality prevents firm conclusions about effectiveness. Its assessment of herbal products is separate from its discussion of acupuncture and tai chi; evidence for those practices cannot establish efficacy for medicinal preparations. In interpreting such uncertainty, insufficient evidence is distinct from demonstrated ineffectiveness: an imprecise or methodologically compromised study may not resolve whether a clinically important benefit exists, whereas a sufficiently precise estimate can exclude a benefit of a specified magnitude for the intervention and outcome tested. (nccih.nih.gov)

Intrinsic Toxicity and Medicine Interactions

Intrinsic toxicity arises from constituents of a correctly identified medicinal ingredient; contamination introduces extraneous substances, while substitution exposes the recipient to a different material. These mechanisms can overlap without being interchangeable. Aristolochic acids, naturally present in certain Aristolochia species, are potent nephrotoxins and carcinogens: correct identification does not eliminate their hazard. Conversely, the US Food and Drug Administration has documented renal-failure outbreaks involving confusion between similarly named materials or misidentified ingredients. Such events combine an identity failure with the intrinsic toxicity of the substituted plant. NCCIH separately identifies contaminants and manufacturing errors as causes of harm in Chinese herbal products. (accessdata.fda.gov)

Aristolochic-acid exposure can produce irreversible kidney damage and is associated with cancers of the renal pelvis, ureter, and bladder. Its metabolites form DNA adducts—chemical attachments to DNA—which provide evidence of exposure in affected tissues. Low-level exposure may precede recognizable injury by years, making the absence of immediate symptoms an unreliable indicator of safety. A different toxicity pattern occurs with he shou wu, commonly described in medical reports as Polygonum multiflorum. The NIH LiverTox assessment, updated on August 18, 2020, classifies it as an established cause of clinically apparent liver injury. Reported onset ranges from a few days to six months; injury is generally hepatocellular or mixed, and some cases progress to liver failure. The precise mechanism remains unresolved, although association with the HLA-B*35:01 allele supports a role for individual immune susceptibility. (accessdata.fda.gov)

Acute toxicity and allergic reactions require separate explanations. Hong Kong’s Centre for Health Protection describes aconitine poisoning from aconite-containing materials such as chuan wu, cao wu, and fu zi, with manifestations including numbness, vomiting, hypotension, and potentially fatal cardiac arrhythmias. Processing reduces toxicity but does not make excessive exposure harmless. He shou wu preparations can also cause abdominal pain, diarrhea, nausea, and vomiting, apart from liver injury. For an immune-mediated example, Jun-Da Li and colleagues reported in 2021 a woman who experienced two episodes of anaphylaxis within an hour of consuming royal jelly. Skin testing, basophil activation, and protein analysis implicated major royal jelly protein 3. This substance-specific finding does not establish that unrelated animal-derived materials share the same allergenic risk. (chp.gov.hk)

Medicine interactions may be pharmacokinetic—altering absorption, metabolism, or elimination—or pharmacodynamic, altering physiological effects without necessarily changing drug concentrations. Human measurements distinguish demonstrated interactions from mechanisms inferred from laboratory assays. In a 2005 study by Xiaochun Wu and colleagues, 52 kidney-transplant recipients received berberine alongside cyclosporine and 52 received cyclosporine without berberine. Final cyclosporine trough concentrations were 29.3% higher in the berberine group; a six-person pharmacokinetic component found a 34.5% increase in total exposure. CYP3A4 inhibition was proposed as the explanation, rather than directly established by those measurements. These results concern administered berberine, not every crude material or formula containing it. (pubmed.ncbi.nlm.nih.gov)

Pharmacodynamic interactions include additive disturbances of electrolyte balance. Licorice root contains glycyrrhizin, which can cause potassium depletion and serious cardiac effects, particularly with substantial or prolonged exposure. Combining licorice with potassium-lowering diuretics or corticosteroids can intensify potassium loss. Interactions are not invariably additive, however. Chun-Hua Zhou and colleagues’ 2018 open-label study of 20 healthy men found that seven days of a particular danshen capsule preparation reduced clopidogrel exposure and measured antiplatelet activity; clopidogrel exposure to the last sampling point fell by 50.3%. Enzyme induction was suggested as a mechanism. The preparation, short observation period, and volunteer population delimit the finding; it does not establish the interaction magnitude for other danshen products or long-term clinical outcomes. (nccih.nih.gov)

Safety evidence is especially incomplete for pregnancy, breastfeeding, and children. NCCIH notes that many supplements have not been tested in these populations and that pediatric adverse effects may differ from those in adults. For licorice specifically, substantial consumption during pregnancy has been associated with earlier delivery, while breastfeeding safety remains poorly characterized. Evidence for prolonged exposure also differs by ingredient: delayed aristolochic-acid injury and glycyrrhizin-related cardiac effects demonstrate hazards that brief observation can miss. Consequently, short-term tolerability data cannot establish reproductive, developmental, or long-term safety for a materially different preparation or exposure duration. (nccih.nih.gov)

Contaminants, Adulteration, and Quality Standards

Contaminants are controlled as distinct analytical targets rather than as a single measure of “purity.” Lead, cadmium, mercury, and arsenic—the last a metalloid—may enter botanical materials through environmental exposure or processing; their presence as contaminants must be distinguished from elements intrinsic to intentionally included mineral ingredients. Pesticide residues require separate, compound-specific testing. Microbiological examinations assess microbial counts and specified organisms, whereas mycotoxin assays detect toxic fungal metabolites, including aflatoxins: these are different endpoints from the detection of living mould. Foreign matter includes soil, stones, insects, packaging fragments, and plant parts other than those specified for the medicinal material. The World Health Organization (WHO) treats these categories separately in its 2007 guidance on contaminants and residues. (cmro.gov.hk)

Adulteration and incorrect identity present different problems from environmental contamination. Undeclared synthetic drugs are additions outside the stated composition, not inherent constituents of traditional formulas; substitution with an incorrect species or medicinal part is an identity failure, whether accidental or deliberate. A Hong Kong toxicology-laboratory study reviewing referrals from January 2005 through December 2015 identified 404 cases involving 487 adulterated proprietary Chinese medicines or health products. Investigators recorded 1,234 adulterants, including sibutramine, glibenclamide, corticosteroids, and nonsteroidal anti-inflammatory drugs. Because the study examined referred cases subsequently confirmed to involve adulteration, its figures do not estimate adulteration prevalence across the retail market. (pmc.ncbi.nlm.nih.gov)

A pharmacopoeial monograph defines a named material through its source, medicinal part, identification characteristics, test methods, and acceptance criteria. Representative sampling precedes laboratory measurement: a satisfactory result from an unrepresentative portion cannot establish the quality of an entire batch. WHO’s 2011 Quality control methods for herbal materials addresses the uneven composition of crude materials by specifying sampling from different containers and from the top, middle, and bottom of selected packages, with damaged containers sampled separately. Visual and microscopic examinations complement chemical tests because neither constituent measurements nor contaminant assays alone establish identity. (cmro.gov.hk)

Basic physicochemical measurements answer different questions. Water-content measurements help assess storage stability; loss on drying may also include volatile substances and is therefore not always equivalent to water content. Total ash measures the inorganic residue after ignition, including both naturally occurring minerals and extraneous inorganic material. Acid-insoluble ash particularly indicates siliceous matter such as sand. Extractive values measure material dissolved by a specified solvent under defined conditions, while constituent assays quantify selected compounds. These measurements require material-specific interpretation: a high extractive value is not itself evidence of greater therapeutic activity, and a marker assay does not replace contaminant testing. (iris.who.int)

The Hong Kong Department of Health launched the Hong Kong Chinese Materia Medica Standards (HKCMMS) project in 2002 to develop safety and quality reference standards for commonly used materials. Its monographs combine source descriptions and identification with tests, extractive values, and assays. Aflatoxin testing, for example, uses high-performance liquid chromatography with fluorescence detection to quantify aflatoxins B₁, B₂, G₁, and G₂. Such a targeted assay supplies information that an appearance check or moisture measurement cannot provide. HKCMMS supports raw-material procurement, manufacturers’ quality control, and laboratory testing and certification. (cmro.gov.hk)

WHO guidance and HKCMMS consequently operate at different levels. WHO’s 2007 guidance provides principles, model criteria, and analytical approaches for national authorities to adapt to local circumstances; HKCMMS supplies specifications and methods for particular Chinese medicinal materials. Compliance means that the tested sample meets the specified identity and quality requirements, including applicable contaminant limits—not that every possible hazard has been excluded. Nor does it demonstrate clinical efficacy: in a July 10, 2019 response concerning the project’s scope, Hong Kong’s Department of Health explicitly distinguished its safety and quality parameters from evaluation of therapeutic effectiveness. (iris.who.int)

Regulation and Pharmacovigilance

Regulation distinguishes medicinal materials, finished products, commercial operators, and practitioners rather than placing them under a single licence. In Hong Kong, the Chinese Medicine Ordinance (Cap. 549), passed on 14 July 1999, established a framework encompassing practitioner registration, trader licensing, and proprietary-product registration. These controls address different objects: practitioner registration concerns professional qualifications and conduct; trader licences authorize specified commercial activities; product registration concerns a particular finished medicine. The Chinese Medicine Council of Hong Kong has separate Chinese Medicine Practitioners and Chinese Medicines boards, so authorization to practise does not itself constitute authorization to manufacture or wholesale medicines. (cmchk.org.hk)

Hong Kong’s statutory category of Chinese herbal medicines covers substances listed in Schedules 1 and 2 of the Ordinance. A proprietary Chinese medicine is a finished-dose product whose active ingredients consist solely of specified Chinese herbal medicines or herbal, animal, or mineral materials customarily used by the Chinese, and which meets the Ordinance’s criteria concerning medicinal use or regulation of bodily functions. Retailers and wholesalers of Chinese herbal medicines, and wholesalers and manufacturers of proprietary Chinese medicines, require the relevant trader licences. Section 119 establishes the registration requirement for selling, importing, or possessing proprietary Chinese medicines; separate provisions govern labels and package inserts. Import–export licensing is an additional control, not a substitute for registration or trader licensing: it covers proprietary Chinese medicines and 36 specified herbal medicines—31 from Schedule 1 and five from Schedule 2, including processed Radix Aconiti and Radix Gentianae. (cmro.gov.hk)

In the United States, botanical origin does not determine regulatory classification by itself. Intended use, including representations in labeling, distinguishes a dietary supplement from a drug. Under the framework created by the Dietary Supplement Health and Education Act of 1994, supplements generally do not undergo Food and Drug Administration (FDA) premarket approval. Manufacturers nevertheless remain responsible for meeting applicable safety and labeling requirements. Supplement structure/function claims describe effects on normal bodily structure or function rather than treatment of disease; they require substantiation, a statutory disclaimer, and notification to FDA within 30 days after first marketing with the claim. A product represented explicitly or implicitly as treating, preventing, or curing a specific disease meets the drug definition, even if labeled a supplement. (fda.gov)

A botanical drug follows drug-development requirements rather than acquiring therapeutic authorization from its history of traditional use. FDA’s December 2016 Botanical Drug Development guidance addresses investigational new drug applications and new drug applications, including documentation of source materials, manufacturing controls, and clinical investigation. It accommodates the chemical complexity of botanical mixtures but retains the same standards of safety and efficacy applied to conventional drugs for the same indication. Its botanical category does not encompass every component of Chinese materia medica: animal-derived materials and minerals fall outside the guidance’s definition, as do highly purified or chemically modified botanical substances. (fda.gov)

Pharmacovigilance operates after exposure through adverse-event reporting, investigation, safety alerts, and recalls. For U.S. dietary supplements, the responsible manufacturer, packer, or distributor must submit qualifying serious adverse-event reports received through the label’s contact information within 15 business days; reporting an event does not establish that the product caused it. WHO’s 2004 herbal-medicine monitoring guidance emphasizes identifying ingredients, manufacturers, batches, exposure timing, and concomitant medicines. Multi-ingredient formulas and simultaneous conventional medicines complicate causal attribution, while substitution or contamination can implicate a particular batch rather than the declared formula. Market testing also triggers action without a reported clinical injury: Hong Kong’s published recall notices include herbal medicines exceeding pesticide-residue limits on 3 and 4 March 2025 and Chinese medicine granules contaminated with alkaloids on 17 November 2022. (fda.gov)

Drug Discovery from Medicinal Traditions

Artemisia annua (sweet wormwood), the botanical source of artemisinin, became a research candidate through the investigation of Chinese medicinal literature and prescriptions for febrile illnesses. In 1969, Tu Youyou assembled more than 2,000 herbal, animal-derived, and mineral prescriptions and selected 640 for a collection circulated through China’s national antimalarial research programme, Project 523. Extracts of more than 100 herbs were subsequently tested against rodent malaria. Historical documentation supplied candidates and preparation clues; experimental screening determined whether particular extracts inhibited parasites. The breakthrough therefore involved both inherited medicinal knowledge and laboratory investigation, rather than the direct adoption of an unchanged historical treatment. (nobelprize.org)

A crucial reference was Ge Hong’s fourth-century Zhouhou Beiji Fang, commonly translated as A Handbook of Prescriptions for Emergencies. Its account of qinghao described soaking the material in water and squeezing out its juice, rather than boiling it. After initial A. annua extracts produced inconsistent antimalarial activity, Tu reconsidered this preparation detail and investigated low-temperature extraction with ether instead of the earlier ethanol procedure. The historical water preparation and the experimental ether extraction were not chemically identical: the text prompted a change in laboratory method. On October 4, 1971, extract sample 191 showed complete inhibition in the rodent-malaria experiment. Separation of the extract yielded a neutral fraction that retained antimalarial activity; subsequent monkey experiments also produced encouraging results. These percentages describe experimental parasite inhibition, not a universal human cure rate. (nobelprize.org)

The transition from active plant extract to a defined pharmaceutical required isolation, characterization, and formulation. During 1972, Tu’s team obtained crystalline material from the neutral extract, and silica-gel column chromatography in November yielded a crystal with antimalarial activity, subsequently named artemisinin, or qinghaosu. Early formulation experiments illustrated why identifying an active compound was insufficient by itself: a 1973 trial of artemisinin tablets gave disappointing results, and examination found that the tablets were too hard to disintegrate properly. The team then investigated capsules. In September 1973, chemical modification during structure–activity research produced dihydroartemisinin, extending the work from purification of a natural constituent to investigation of related compounds. (nobelprize.org)

Further derivative development retained the peroxide group essential to antimalarial activity while changing pharmaceutical properties. Dihydroartemisinin provided the basis for oil-soluble artemether and water-soluble artesunate, which were selected for larger-scale trials. Artemisinin derivatives act rapidly but have short biological half-lives. In artemisinin-based combination therapies, a derivative rapidly reduces the parasite burden, while a longer-acting partner medicine eliminates remaining parasites. Such combinations are defined pharmaceutical products containing distinct active substances, not traditional multi-ingredient formulas; their development depended on chemical modification, pharmacological investigation, and clinical assessment. (iris.who.int)

The 2015 Nobel Prize in Physiology or Medicine awarded one half to Tu for discoveries concerning a novel therapy against malaria; the other half went jointly to William C. Campbell and Satoshi Ōmura for discoveries concerning therapies against roundworm infections. This recognition concerned a specific drug-discovery achievement, not unrelated traditional treatments. Evidence for purified artemisinin and tested pharmaceutical derivatives does not establish equivalent efficacy for crude A. annua, compound formulas, or the theoretical framework of traditional Chinese medicine. Following its 2019 evidence review, the World Health Organization opposed the promotion or use of non-pharmaceutical Artemisia preparations for malaria prevention or treatment, citing variable constituent content, potentially insufficient parasite clearance, and concerns about promoting resistance. The plant source, purified compound, derivative, and finished combination medicine consequently remain distinct objects of evidence. (nobelprize.org)

Trade, Institutions, and Knowledge Preservation

Modern commercial manufacture placed Chinese medicinal preparations within new systems of production, branding, and advertising. The United States National Library of Medicine (NLM) documents competition from Western pharmaceutical companies, including Bayer, Hoechst, and Eli Lilly, beginning in the 1880s, followed by Chinese firms entering these commercial markets. The Tianjin Pharmaceutical Factory, founded in 1921, adopted Western methods to produce and market traditional Chinese medicines. An undated advertisement preserved by the NLM promotes its Xiao’er Baishou Pian through images of packaged pills and traditional architecture. Such advertisements document how manufacturers presented familiar medicines to an increasingly modernized population; their therapeutic claims are historical commercial evidence, not independent demonstrations of efficacy. (mainweb.awsprod.nlm.nih.gov)

Retail medicine shops also left material records of the relationship between trade, family enterprise, and medical practice. In Hong Kong, Lui Leung’s Lui Seng Chun building, completed in 1931, accommodated a Chinese medicine shop on the ground floor and family residences above. The shop closed a few years after his death in 1944; the family donated the building to the government in 2003. Since 2012, Hong Kong Baptist University (HKBU) has operated a Chinese medicine and healthcare centre there while retaining important architectural features. Its preservation connects a former commercial pharmacy with contemporary teaching and public interpretation of cultural heritage, rather than preserving only texts detached from their working environment. (amo.gov.hk)

Libraries, teaching institutions, and museums preserve complementary kinds of evidence. The NLM holds more than 2,000 volumes of Chinese medical classics, alongside thousands of public-health items, including posters, scrolls, and pharmaceutical advertisements. These collections support the study of textual transmission, commercial presentation, and changes in medical practice. HKBU’s Bank of China (Hong Kong) Chinese Medicines Centre, established in October 2003 as part of the Dr. & Mrs. Hung Hin Shiu Museum of Chinese Medicine, preserves physical materials: medicinal specimens, decoction pieces, animal-derived substances, voucher specimens, and reference samples associated with the Hong Kong Chinese Materia Medica Standards. Displays of commonly confused materials give teaching a comparative basis, allowing names and written descriptions to be examined alongside actual objects. (mainweb.awsprod.nlm.nih.gov)

Digital databases extend access to these teaching and documentary resources. A 2014 account by Hubiao Chen, Lisa Song, and Yiu On Li described HKBU’s Chinese Medicinal Material Images Database as containing more than 420 representative medicinal species, with photographs, detailed descriptions, and illustrations of macroscopic and microscopic identification. The university’s Chinese Medicine Formulae Images Database, launched in 2018 through collaboration between its School of Chinese Medicine and Library, initially documented 182 formulas. Its records included composition, preparation forms, traditional functions and indications, and mnemonic formula verses. These resources preserve different levels of knowledge: the material database emphasizes recognition of individual substances, while the formula database records how ingredients are organized into prescriptions. Their descriptions of traditional indications document teaching content rather than, by themselves, validate clinical effectiveness. (scholars.hkbu.edu.hk)

The original Encyclopedia of Traditional Chinese Medicine (ETCM), described in a paper published online in 2018, organized 403 herbs, 3,962 formulas, and 7,274 chemical ingredients. It combined resource-survey information, regulatory formula records, literature-derived constituent data, and marker-ingredient specifications from the 2015 Chinese Pharmacopoeia. Relationships between ingredients, predicted molecular targets, and disease-associated genes made the database useful for retrieving information and generating research hypotheses. Its target assignments included computational predictions, however: a searchable association between a formula, a gene, and a disease is not evidence that the formula treats that disease in humans. (academic.oup.com)

Trade statistics require equally explicit boundaries. In a government reply dated July 16, 2025, Hong Kong reported that its 2024 Chinese herbal-medicine imports amounted to 12,182,088 kg, valued at HK$3,489.8 million, while total exports amounted to 2,959,551 kg, valued at HK$692.8 million. These figures describe a specified commodity category and jurisdiction, not worldwide sales of finished Chinese medicines or the entire traditional Chinese medicine sector. Statistical comparisons must identify the reporting year, geographic coverage, product classification, and whether the measure concerns weight, trade value, manufacturing revenue, or services. Hong Kong’s trade-statistics system also distinguishes import values recorded on a cost-insurance-freight basis from export values recorded free on board, making valuation conventions relevant when comparing monetary totals. (info.gov.hk)

Conservation and Sustainable Sourcing

Wild collection affects medicinal species differently according to their growth rates, reproductive biology, harvested parts, and collection intensity. Digging American ginseng (Panax quinquefolius) roots kills the harvested plants; removing reproductive individuals before they replenish a population can therefore reduce subsequent recruitment. The United States Fish and Wildlife Service has documented collectors eliminating local fruit-bearing populations. For liquorice (Glycyrrhiza spp.), a 2018 IUCN account identified heavy machinery used in root collection as a destructive alternative to traditional harvesting practices. Habitat loss and degradation can compound collection pressure by reducing the area available for regeneration. These examples establish risks for particular resources, not a uniform conservation status for all Chinese medicinal materials. Statistics covering medicinal and aromatic plants also include food, cosmetic, and other markets and cannot be attributed entirely to Chinese medicine. (fws.gov)

The Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) regulates cross-border trade in listed species through permits and certificates. Appendix II does not necessarily indicate imminent extinction: it includes species whose trade requires control to avoid exploitation incompatible with survival. Export authorization normally requires findings that specimens were legally acquired and that export will not harm the species’ survival—a non-detriment finding. American ginseng entered Appendix II in 1975 because of concerns about overharvesting for international trade. Its United States export controls include a minimum age of five years for wild and wild-simulated roots and certification by the state or tribe of harvest. Appendix I imposes stricter restrictions: all eight pangolin species entered that appendix effective January 2, 2017, prohibiting commercial international trade in wild-taken specimens. National legislation may impose stricter requirements than the convention. (cites.org)

Cultivation can replace some wild collection, but it does not automatically protect wild populations. An FAO assessment identifies possible countereffects, including environmental degradation, reduced genetic diversity, and weakened economic incentives to conserve wild habitats. Managed wild harvesting instead requires resource assessments, collection limits appropriate to the species, monitoring of regeneration, and adjustment when populations decline. The FairWild Standard combines ecological requirements with collector rights, equitable commercial arrangements, and legal compliance. Supply-chain records support these controls by connecting collection areas, quantities, purchases, processing, and sales; traceability documentation must be accompanied by field assessment rather than treated as evidence of population recovery in itself. (fao.org)

Investigated substitutes include manufactured constituents rather than another wild medicinal species. A 2024 experimental study, for example, produced tauroursodeoxycholic acid, a constituent of bear bile, from chicken bile using immobilized enzymes. Such work investigates a production route that avoids extracting that constituent from bears; it does not establish that the resulting substance is clinically interchangeable with whole bear bile or every preparation containing it. Conservation effects also depend on adoption. A 2022 study of consumers in China examined switching between wild, farmed, and synthetic bear-bile products, illustrating why technical availability alone does not demonstrate displacement of wild sourcing. (link.springer.com)

Conservation status, trade legality, material authenticity, animal welfare, and clinical effectiveness answer different questions. Appendix II listing is not equivalent to a threatened-species assessment, while a permit concerns a particular shipment rather than proof of medicinal benefit. Authentic identification establishes what material is present, not whether its collection was sustainable. Animal welfare likewise concerns individual animals and collection methods, rather than only species survival. In a June 11, 2014 legislative reply, Hong Kong’s government explicitly distinguished endangered-species trade controls from regulation of bear-bile extraction methods. Neither legal sourcing nor a conservation-oriented substitute establishes therapeutic equivalence without product-specific evidence. (cites.org)

References

1. TCDO: A Community-Based Ontology for Integrative Representation and Analysis of Traditional Chinese Drugs and Their Propertiespmc.ncbi.nlm.nih.gov
2. New Perspectives on Chinese Herbal Medicine (Zhong-Yao) Research and Developmentpmc.ncbi.nlm.nih.gov
3. On the concept of bencaopubmed.ncbi.nlm.nih.gov
4. A concise classification of bencao (materia medica)pubmed.ncbi.nlm.nih.gov
5. Traditional Chinese Medicine: What You Need To Knownccih.nih.gov
6. Hong Kong Good Manufacturing Practice Guidelines for Proprietary Chinese Medicinescmchk.org.hk
7. Points to note when purchasing proprietary Chinese medicinescmro.gov.hk
8. Regulation of Chinese Medicinescmro.gov.hk
9. A concise classification of bencao (materia medica)pmc.ncbi.nlm.nih.gov
10. From religious manual to herbal pharmacopoeia: a textual study of the formation and transformation of Shennong’s Classic of Materia Medicatmrjournals.com
11. Traditional Chinese Medicine: Shang han lunnlm.nih.gov
12. From under the elbow to pointing to the palm: Chinese metaphors for learning medicine by the book (fourth–fourteenth centuries)cambridge.org
13. Memory of the World Register: Ben Cao Gang Mu (Compendium of Materia Medica)media.unesco.org
14. Traditional Chinese Medicinenlm.nih.gov
15. Priest Gyōnen 700th Memorial Special Exhibition: The Buddhist Legacy of Jianzhen (Ganjin) and His Successorskyohaku.go.jp
16. Tracing the Origin of Kampo, Japan’s Traditional Medicineokayama-u.ac.jp
17. General Noticesdh.gov.hk
18. Lists of Chinese Materia Medica in HKCMMScmro.gov.hk
19. Identification of Differential Compositions of Aqueous Extracts of Cinnamomi Ramulus and Cinnamomi Cortexpmc.ncbi.nlm.nih.gov
20. Radix Angelicae Sinensisdh.gov.hk
21. Defined Organism Substance — Rhizoma Curcumae Longaewebprod.hc-sc.gc.ca
22. Chinese Medicine Specimen Database — Giant Cinnamon Barksys01.lib.hkbu.edu.hk
23. Medicinal Material Images Database — Ginkgo Leafsys01.lib.hkbu.edu.hk
24. Lonicerae Japonicae Flos versus Lonicerae Floscmro.gov.hk
25. Chinese Magnoliavine Fruitherbaltcm.sn.polyu.edu.hk
26. Qualitatively and quantitatively comparing secondary metabolites in three medicinal parts derived from Poria cocosscholars.hkbu.edu.hk
27. Licorice: Resources, applications in ancient and modern times — publication abstractcmro.gov.hk
28. Quality control methods for medicinal plant materialswho.int
29. Validation of the ITS2 region as a novel DNA barcode for identifying medicinal plant speciespubmed.ncbi.nlm.nih.gov
30. Constructing a DNA barcode reference library for southern herbs in China: A resource for authentication of southern Chinese medicinepmc.ncbi.nlm.nih.gov
31. DNA barcoding identification of commercial decoctions in traditional Chinese medicinecastjournals.cast.org.cn
32. Enhancing Testing Laboratory Engagement in Plant DNA Barcoding through a Routine Workflow—A Case Study on Chinese Materia Medica (CMM)pmc.ncbi.nlm.nih.gov
33. WHO guidelines on good manufacturing practices for the manufacture of herbal medicineswho.int
34. The formation of daodi medicinal materialsscholars.hkbu.edu.hk
35. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plantsiris.who.int
36. Effect of Harvest Time on Growth and Bioactive Compounds in Salvia miltiorrhizapmc.ncbi.nlm.nih.gov
37. Bioactive components of the roots of Salvia miltiorrhizae: Changes related to harvest time and germplasm linedoi.org
38. Chinese Medicine Hospital Project — Chinese Medicines and Pharmacyhealthbureau.gov.hk
39. WHO international standard terminologies on traditional Chinese medicinewho.int
40. WHO傳統醫學國際標準術語(中醫) — XML Representationbuild.fhir.org
41. WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Regionasiantherapies.org
42. Medicinal Plant Images Database — Palmleaf Rhubarbsys01.lib.hkbu.edu.hk
43. Chinese Medicinal Material Images Database — Liquorice Rootsys01.lib.hkbu.edu.hk
44. Medicinal Plant Images Database — Panax ginsengsys01.lib.hkbu.edu.hk
45. Chinese Medicine Formulae Images Database — Mulberry Leaf and Chrysanthemum Beveragesys01.lib.hkbu.edu.hk
46. A unique issue in the standardization of Chinese Materia Medica: processingcmro.gov.hk
47. Seeing the unseen of Chinese herbal medicine processing (Paozhi): advances in new perspectivespmc.ncbi.nlm.nih.gov
48. Influence of honey-roasting on the main pharmacological activities and the water-soluble active glycosides of licoricepubmed.ncbi.nlm.nih.gov
49. A comparative study on the traditional Indian Shodhana and Chinese processing methods for aconite roots by characterization and determination of the major componentspubmed.ncbi.nlm.nih.gov
50. Monoester-Diterpene Aconitum Alkaloid Metabolism in Human Liver Microsomes: Predominant Role of CYP3A4 and CYP3A5pubmed.ncbi.nlm.nih.gov
51. Dissecting chemical markers for controlling "Paozhi" method of traditional Chinese medicine with untargeted metabolomics: Vinegar-baked Euphorbia kansui as a case studypubmed.ncbi.nlm.nih.gov
52. Total recall of processed Radix Aconiti Lateralisdh.gov.hk
53. HKBU School of Chinese Medicine launches territory's first "Chinese Medical Formulae Images Database" for free worldwide accesshkbu.edu.hk
54. 中藥方劑圖像數據庫 - 記錄頁面：四君子湯sys01.lib.hkbu.edu.hk
55. Chinese Medicine Formulae Images Database - Detail Page: Si Jun Zi Tangsys01.lib.hkbu.edu.hk
56. Chinese Medicine Specimen Database - Detail Page: Liu Wei Di Huang Wansys01.lib.hkbu.edu.hk
57. Guide for Completion of Application Form for Registration of Proprietary Chinese Medicinescmchk.org.hk
58. Key Technical Issues of Herbal Medicinesiris.who.int
59. A novel concept for detoxification: complexation between aconitine and liquiritin in a Chinese herbal formula ('Sini Tang')pubmed.ncbi.nlm.nih.gov
60. WHO guidelines on good herbal processing practices for herbal medicineswho.int
61. Good Manufacturing Practice (GMP) for Proprietary Chinese Medicinescmro.gov.hk
62. WHO guidelines for selecting marker substances of herbal origin for quality control of herbal medicineswho.int
63. Reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal productsema.europa.eu
64. Quality assurance for Chinese herbal formulae: standardization of IBS-20, a 20-herb preparationpmc.ncbi.nlm.nih.gov
65. Results of Hong Kong Chinese Materia Medica Standards (Phase 1) announceddh.gov.hk
66. Assay Interference by Chemical Reactivity — Assay Guidance Manualncbi.nlm.nih.gov
67. Assay Interference by Chemical Reactivity — Assay Guidance Manualncbi.nlm.nih.gov
68. Technical guidelines for non-clinical pharmacological research of traditional Chinese medicine (TCM) formulaepmc.ncbi.nlm.nih.gov
69. Technical guidelines for non-clinical pharmacological research of traditional Chinese medicine (TCM) formulaed-nb.info
70. Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humanspubmed.ncbi.nlm.nih.gov
71. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemiapmc.ncbi.nlm.nih.gov
72. TCMSP: a database of systems pharmacology for drug discovery from herbal medicinestcmsp-e.com
73. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trialspmc.ncbi.nlm.nih.gov
74. 口服或皮肤外用中草药以治疗儿童和成人特应性湿疹cochrane.org
75. Import Alert 54-10accessdata.fda.gov
76. Aristolochic Acids—Cancer-Causing Substancescancer.gov
77. Aristolochic Acids—15th Report on Carcinogensncbi.nlm.nih.gov
78. Polygonum Multiflorum—LiverToxncbi.nlm.nih.gov
79. Poisoning Watch, Volume 4, Number 1, December 2011chp.gov.hk
80. A Case of Anaphylaxis Caused by Major Royal Jelly Protein 3 of Royal Jelly and Its Cross-Reactivity with Honeycombpubmed.ncbi.nlm.nih.gov
81. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic studypubmed.ncbi.nlm.nih.gov
82. Licorice Root: Usefulness and Safetynccih.nih.gov
83. Licorice Rootgovinfo.gov
84. Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteerspubmed.ncbi.nlm.nih.gov
85. Using Dietary Supplements Wiselynccih.nih.gov
86. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residuesiris.who.int
87. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residuesiris.who.int
88. Herbal Medicines and Heavy Metalscmro.gov.hk
89. Adulteration of proprietary Chinese medicines and health products with undeclared drugs: experience of a tertiary toxicology laboratory in Hong Kongpmc.ncbi.nlm.nih.gov
90. Quality control methods for herbal materialsiris.who.int
91. Hong Kong Chinese Materia Medica Standardscmro.gov.hk
92. Introduction of Hong Kong Chinese Materia Medica Standards (Volume 10) & Latest Developmentscmro.gov.hk
93. HKCMMS listing criteriaaccessinfo.hk
94. Handbook of the Application for Chinese Medicines Trader Licencescmchk.org.hk
95. 2015 Annual Report: Regulation of Chinese Medicine Practitionerscmchk.org.hk
96. Chinese Medicine Council of Hong Kong: Regulation of Chinese Medicinecmchk.org.hk
97. Import and Export Control of Chinese Medicinescmro.gov.hk
98. Questions and Answers on Dietary Supplementsfda.gov
99. Notifications for Structure/Function and Related Claims in Dietary Supplement Labelingfda.gov
100. Botanical Drug Development Guidance for Industryfda.gov
101. Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Actfda.gov
102. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systemsiris.who.int
103. Chinese Medicines Recallcmro.gov.hk
104. Tu Youyou – Biographical - NobelPrize.orgnobelprize.org
105. The Nobel Prize in Physiology or Medicine 2015 - Advanced information - NobelPrize.orgnobelprize.org
106. Global Malaria Programme: The use of non-pharmaceutical forms of Artemisiairis.who.int
107. Nonclinical overview of artemisinin derivativesextranet.who.int
108. Malariawho.int
109. The use of non-pharmaceutical forms of Artemisiawho.int
110. Traditional Chinese Medicinemainweb.awsprod.nlm.nih.gov
111. Traditional Chinese Medicine: Xiao’er Baishou Pian advertisementnlm.nih.gov
112. Declared Monuments in Hong Kong—Kowloon: Lui Seng Chunamo.gov.hk
113. Introduction of Bank of China (Hong Kong) Chinese Medicines Centrecmmuseum.hkbu.edu.hk
114. Establishment of Chinese Medicinal Material Images Databasescholars.hkbu.edu.hk
115. Launch of the Chinese Medicine Formulae Images Databaselibrary.hkbu.edu.hk
116. LCQ12: Registration of proprietary Chinese medicines and import and export of Chinese herbal medicinesinfo.gov.hk
117. Ginseng | U.S. Fish & Wildlife Servicefws.gov
118. Operation Root Cause: Diggers, dealers, and the case for wild ginsengfws.gov
119. Wild at home: threats and opportunities from the trade in wild plantsiucn.org
120. New report highlights the opportunities for sustainable trade of wild plant ingredients amid a surge in its global demandiucn.org
121. Biodiversity and the Ecosystem Approach in Agriculture, Forestry and Fisheriesfao.org
122. FairWild Standard overviewfairwild.org
123. FairWild Standard Version 2.0fairwild.org
124. Synthesis of TUDCA from chicken bile: immobilized dual-enzymatic system for producing artificial bear bile substitutelink.springer.com
125. Understanding why consumers in China switch between wild, farmed, and synthetic bear bile productspmc.ncbi.nlm.nih.gov
126. 答覆立法会问题：含熊胆成分的中成药产品healthbureau.gov.hk